Lab-grown bone from own stem cells for early femoral head necrosis
Tests engineered bone made from a person's own stem cells in early femoral head necrosis.
Key facts
- Who runs it
- The First Affiliated Hospital of Xinxiang Medical College
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Avascular Necrosis of Femur Head
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 20 Apr 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Tissue-engineered bone
- Record updated
- 4 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early femoral head necrosis that was not caused by an injury. Femoral head necrosis means bone death in the top of the thigh bone at the hip. The hip must still hurt despite conservative treatment.
- Age
- 20 to 65 years
- Sex
- All sexes
- Disease stage
- ARCO stage II femoral head necrosis, not caused by injury. People must be able to walk more than 50 meters without crutches or a walking stick.
- Earlier treatment
- People must have had conservative treatment (such as physical therapy or pain drugs) for more than 2 weeks, with ongoing hip pain. People cannot join after hip replacement or other hip surgery, or after a hip injection or hip surgery within 6 months.
Main reasons for not taking part
- Hip injury that affected the target hip, or the femoral head has already collapsed or fused
- Use of opioids or glucocorticoids for the hip within 30 days before screening
- Active cancer, or cancer within 5 years (except squamous or basal cell skin cancer)
- Positive test for hepatitis B, hepatitis C, HIV (AIDS) or syphilis
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Capable of understanding and voluntarily signing the informed consent form before the study
- Meets the diagnostic criteria in the "Clinical Diagnosis and Treatment Guidelines for Adult Femoral Head Necrosis in China (2020)"
- Age range: 20 - 65 years old (inclusive of boundary values), gender not restricted
- Staged as ARCO II stage
- Non-traumatic femoral head necrosis
- Has received conservative treatment (such as physical therapy, blood-activating, analgesic drugs, etc.) for more than 2 weeks, and the target hip joint still shows persistent pain symptoms
- The subjects are usually able to move, not bedridden or in a wheelchair for a long time, and can walk more than 50 meters without the help of crutches or walking sticks
- During the trial period and within 90 days after the surgery, the subjects have no pregnancy plans and voluntarily take effective contraceptive measures
Who cannot take part
- In the six months prior to screening, there were obvious injuries involving the target hip joint
- The target hip joint had suppurative arthritis or a previous history
- The subject was treating the target hip joint, and within 30 days before screening, had used opioids or glucocorticoids for treatment; or was required to use opioids or glucocorticoids for long-term treatment during the study period
- Patients who had received any drug injection or surgical treatment in the hip joint (both sides or any one side) within 6 months before the treatment start
- Started using drugs such as cilostazol for promoting blood circulation and anticoagulation therapy 8 weeks before screening
- Note: If antihypertensive drugs or anticoagulant drugs such as cilostazol were used for treatment for ≥ 8 weeks before screening, they could be used at a stable dose during the study period
- The subject had any type of active malignant tumor and was receiving systemic chemotherapy; or within 5 years before screening, was diagnosed with cancer (excluding squamous cell carcinoma or basal cell carcinoma of the skin)
- Gastrointestinal underlying diseases: having a history of gastrointestinal bleeding or perforation after using non-steroidal anti-inflammatory drugs (NSAIDs); subjects with active gastrointestinal ulcer bleeding within 30 days before enrollment, or who have had recurrent ulcer bleeding in the past
- Those who have participated in any other clinical trials within 3 months before screening
- Based on the researcher's judgment, the subjects had a history of trauma and the injury affected the target hip joint
- The subject's femoral head necrosis was due to other diseases affecting the hip joint (such as rheumatoid arthritis, psoriatic arthritis, gouty arthritis, symptomatic cartilage calcification, bone necrosis, active infection), or according to the researcher's judgment, peripheral or central nervous system lesions that might affect the assessment of pain and function of the target hip joint (such as back pain, knee joint disease, intervertebral disc protrusion, sciatic nerve pain, fibromyalgia, diabetic neuropathy, etc.)
- Those who had a history of hip joint replacement, arthroplasty, or other hip joint surgeries, or planned to undergo surgical treatment of any lower limb/hip joint during the study period
- During the screening period, the target hip joint had active joint infection or skin ulceration, infection in the surgical area, or any significant chronic skin disease that might interfere with the surgical procedure
- The subject had a disease requiring systemic glucocorticoid treatment
- Uncontrolled hypertension (defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg after standardized antihypertensive drug treatment)
- Positive hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, syphilis antibody tests
- Those who are known or suspected to be allergic to the active or inactive ingredients of the research drug
- Allergic to the test drug or having a history of hypersensitivity reaction
- Having a clear history of mental disorder, or having a history of abuse of psychotropic drugs or drug addiction
- Alcohol (defined as drinking more than 2 units per day/ more than 14 units per week, 1 unit being equivalent to 360ml of beer or 45ml of 40% alcohol content spirits or 150ml of wine) or drug abusers; or those with mental disorders
- Abnormal liver and kidney function: At the time of screening, AST or ALT > 2 × upper limits of normal (ULN); or serum creatinine > 1.5 × ULN, or creatinine clearance rate ≤ 50 mL/min
- Note: For men, the creatinine clearance rate (mL/min) = [(140 - age) × weight (kg)] / [0.818 × Cr (μmol/L)]; for women, the creatinine clearance rate (mL/min) = male creatinine clearance rate (mL/min) × 0.85
- According to the researcher's judgment, before enrollment, 12-lead electrocardiogram (ECG) showed clinically significant abnormalities; including QTc (QTcB) > 450 ms, or heart rate > 100 bpm, or QRS > 120 ms, or PR > 220 ms
- Basic cardiovascular diseases: Within 6 months before enrollment, had experienced the following cardiovascular events: myocardial infarction or coronary artery bypass surgery or traumatic coronary artery reperfusion surgery or stroke; unstable angina pectoris; variant angina pectoris; symptomatic congestive heart failure (New York Heart Association cardiac function grade III-IV or ejection fraction ≤ 35%)
- Pregnant women, lactating women, and women of childbearing age who have not undergone sterilization surgery/are not in menopause/are unwilling to use medically approved effective contraceptive measures during the study period; men who have not undergone sterilization surgery/are unwilling to use medically approved effective contraceptive measures during the study period
- The femoral head of the target hip joint had obvious necrosis, collapse, joint fusion, etc
- The target hip joint had obvious joint effusion
- Subjects unable to avoid non-habitual physical activities (such as starting new weightlifting exercises)
- Other situations deemed unsuitable for participation in this trial by the investigator
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 20 and 65 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The commercial decalcified bone scaffold combined with the patient's autologous bone marrow mesenchymal stem cells was used for in vitro culture to form tissue-engineered bone, and the effect of this tissue-engineered bone in early non-traumatic femoral head necrosis was explored.
The group in the trial
- Tissue-engineered bone to repair Avascular Necrosis of Femur HeadTreatment being tested
Tissue-engineered bone with autologous bone marrow mesenchymal stem cells to repair Avascular Necrosis of Femur Head
Treatment: Tissue-engineered bone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Transformation of Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Avascular Necrosis of Femur Head
- Plain-language title
- Lab-grown bone from own stem cells for early femoral head necrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07101562, who can take part
- Record updated
- 4 May 2026